Reduced Risk of Chronic Graft-Versus-Host Disease (cGVHD) by Rabbit Anti-Thymocyte Globulin (ATG) in Patients Undergoing Matched Sibling Donor Transplantation in Hematological Malignancies

Shu Fang; Nan Wang; Lili Wang; Jishan Du; Jingjing Yang; Yanan Wen; Yan Wei; Kun Qian; Hao Wang; Yifan Jiao; Chunji Gao; Liping Dou

doi:10.12659/AOT.937356

11 October 2022 : Original article

Reduced Risk of Chronic Graft-Versus-Host Disease (cGVHD) by Rabbit Anti-Thymocyte Globulin (ATG) in Patients Undergoing Matched Sibling Donor Transplantation in Hematological Malignancies

Shu Fang^12ABCDEF, Nan Wang^23ABCF, Lili Wang^2ABCD, Jishan Du^23BCF, Jingjing Yang^23BCF, Yanan Wen^23BCF, Yan Wei^23BCF, Kun Qian^12BCD, Hao Wang^23ABF, Yifan Jiao^23BCF, Chunji Gao^12ACEG*, Liping Dou^2ABDEG

DOI: 10.12659/AOT.937356

Ann Transplant 2022; 27:e937356

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 3 Univariate analysis of risk factors for grades 2–4 aGVHD and cGVHD in all patients.

	Grades 2–4 aGVHD			Chronic GVHD
	HR	95% CI	p	HR	95% CI	p
ATG vs non-ATG	1.573	0.748–3.307	0.232	0.222	0.093–0.530	0.001
Recipient age (≥ median vs < median)	0.962	0.457–2.021	0.918	0.930	0.427–2.027	0.856
Donor age (≥ median vs < median)	1.140	0.542–2.396	0.730	1.040	0.531–2.039	0.908
Donor-recipient gender match
Female to male vs others	1.091	0.493–2.412	0.830	0.719	0.335–1.542	0.397
Donor-recipient ABO match
Mismatch vs match	1.858	0.885–3.902	0.101	1.153	0.576–2.308	0.688
Diagnosis (ALL vs others)	1.243	0.562–2.748	0.591	0.396	0.153–1.023	0.056
Time interval between diagnosis and HSCT
≥6 m vs <6 m	1.806	0.845–3.859	0.127	0.679	0.344–1.339	0.264
Cytogenetic risk
High vs favorable/intermediate	1.854	0.868–3.964	0.111	0.325	0.126–0.843	0.021
Disease status at HSCT
Untreated/refractory/relapsed vs CR	0.595	0.206–1.715	0.336	1.531	0.692–3.386	0.293
Disease risk index
High/very high vs low/intermediate	1.556	0.728–3.322	0.254	0.313	0.121–0.810	0.017
MNC (≥ median vs < median)	1.315	0.622–2.781	0.473	0.535	0.268–1.068	0.076
CD34 (≥ median vs < median)	2.026	0.935–4.391	0.073	0.474	0.234–0.958	0.038
aGVHD (Grades 2–4 vs grades 0–1)				0.828	0.403–1.704	0.608
ATG – anti-thymocyte globulin; aGVHD – acute graft-versus-host disease; GVHD – graft-versus-host disease; HSCT – hematopoietic stem cell transplantation; ALL – acute lymphoblastic leukemia; CR – complete remission; MNCs – mononuclear cells.

Back to the Article

Reduced Risk of Chronic Graft-Versus-Host Disease (cGVHD) by Rabbit Anti-Thymocyte Globulin (ATG) in Patients Undergoing Matched Sibling Donor Transplantation in Hematological Malignancies

Your Privacy